Financial

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of July 31, 2023

PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of July 31, 2023 (pursuant to Article L. 233-8 II of […]

Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights. “a major scientific breakthrough that happens once every decade or so” Tweet this “The second quarter of 2023 was a […]

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), today announced the closing of its previously announced exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, in exchange […]

iRhythm Technologies Announces Second Quarter 2023 Financial Results

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and six months ended June 30, 2023. Second Quarter 2023 Financial Results Revenue of $124.1 million, […]

Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease

CARLSBAD, Calif., Aug. 3, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD). This builds on the companies’ existing collaboration focused on the […]

Artivion Reports Second Quarter 2023 Financial Results

ATLANTA, Aug. 3, 2023 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the second quarter ended June 30, 2023. “Our second quarter results reflect the strength of our business commercially, operationally, and financially. We delivered double-digit constant currency revenue growth year-over-year […]

United Therapeutics Corporation Reports Second Quarter 2023 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter […]

Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. “Our third quarter […]

Synaptive Medical Welcomes Provincial Investment to Expand Manufacturing and R&D Activities

TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) — Synaptive Medical has received $900,000 in support from the Ontario government through the Ontario Together Fund. This funding will support Synaptive Medical’s $2.8 million project to expand manufacturing and research and development activities related to the company’s head-only Magnetic Resonance Imaging (MRI) system. […]